PUMA BIOTECHNOLOGY (PBYI) Stock: Buy, Sell, or Hold?
PBYI - PUMA BIOTECHNOLOGY INC
$9.51
-0.33 (-3.35%)
▼
5d:
-2.66%
30d:
-1.86%
90d:
+15.69%
HOLD
MODERATE Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When PBYI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PBYI trades at premium valuation expecting 17.8% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: PBYI trades at premium valuation expecting 17.8% growth. Hold existing positions but don't chase. Wait for better entry.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$2.23
Based on -16.2% avg growth
INTRINSIC VALUE TODAY
$1.38
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBYI is currently trading at $9.51, which is considered fair relative to its 30-day fair value range of $9.18 to $9.72. From a valuation perspective, the stock is trading at a premium (Forward PE: 27.2) compared to its historical average (16.6). At these levels, the market is pricing in 17.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PBYI is in a strong uptrend. Immediate support is located at $9.02, while resistance sits at $10.10. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: PBYI scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $6.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PBYI is in a strong uptrend. Immediate support is located at $9.02, while resistance sits at $10.10. Short-term momentum is weak, with the stock down 3.4% recently.
Market Sentiment: PBYI scores 39/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (16th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $6.00. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$9.18 -
$9.72
Company Quality Score
53/100
(HOLD)
Options IV Signal
16th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
47.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 16th percentile)
- BEARISH: Weak technical setup (39/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.4%)
- BEARISH: Trading 36.9% above Wall St target ($6.00)
- NEUTRAL: Trading at premium valuation - market expects 17.8% growth which is achievable
Trading Range Analysis
30-Day Trading Range
$9.18 -
$9.72
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.76
(8.0%)
Support & Resistance Levels
Support Level
$9.02
Resistance Level
$10.10
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
27.17
Wall Street Target
$6.00
(-36.9%)
Revenue Growth (YoY)
7.8%
Earnings Growth (YoY)
35.8%
Profit Margin
11.6%
Valuation Premium vs History
+17.8% premium
PE vs Historical
27.2 vs 16.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+17.8%
(market-implied from PE analysis)
1-Year Target
$11.20
(+18%)
2-Year Target
$13.20
(+39%)
3-Year Target
$15.55
(+64%)
3-Yr Target (if PE normalizes)
(PE: 27→17)
PE COMPRESSION
$9.50
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 27.2, Growth: -36.4%)
$6.93
(+-27%)
Base:
(SPY PE: 20.4, Growth: -36.4%)
$5.21
(-45%)
Bear:
(PE: 16.6, Growth: -36.4%)
$4.24
(-56%)
📈
Valuation based on Current Earnings
Trailing PE: 19.29 | Current EPS (TTM): $0.51
Bull Case
$7.43
(-22%)
Analyst growth -31.4%, PE expands to 21.2
Base Case
$6.75
(-29%)
Market implied -31.4%, PE stable at 19.3
Bear Case
$6.69
(-30%)
Severe decline -20.0%, PE contracts to 16.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 03, 2026 9:55 PM ET
Data refreshes hourly during market hours. Next update: 10:55 PM
Data refreshes hourly during market hours. Next update: 10:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBYI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 54 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$851 | 48 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 67 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$29 | 49 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 62 BUY |
